Therapies Targeting Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Studying the tumor microenvironment (TME) helps improve our understanding of cancer. Myeloid-derived suppressor cells (MDSCs) exist within the TME and maintain cancer progression.
Comparison of Viability Detection Methods Via Morphological Observation
Determining cell viability is a vital component in many biological experiments and one of the most common methods for this measurement is the trypan blue (TB) exclusion assay.
An Optimized Workflow for Generating Anti-CD19 CAR T Cells by mRNA Electroporation
Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary and promising approach for cancer treatment. However, its potential is limited by technical challenges and safety risks associated with viral transduction–based CAR T-cell generation workflows.
Accelerating Cancer Research Through Comprehensive Genomic Analysis
While next-generation sequencing is becoming increasingly routine in cancer research laboratories, it fails to address a number of key genomic drivers or markers of cancer, such as structural variations, DNA methylation and transcript isoforms.
PD-1/PD-L1 Combination Therapy in Cancer Treatment
Cancer immunotherapy, especially the use of immune checkpoint inhibitors, has been successful in improving the treatment landscape of malignancies.
High-Throughput, Multi-Parametric Analysis Accelerates Antibody Discovery Workflows
Download this whitepaper to discover how high-throughput flow cytometry can provide quantitative data on binding, antibody internalization and antibody-dependent cell-mediated cytotoxicity, antibody-dependent cellular phagocytosis and T-cell activation.
Streamline Antibody Labeling Workflows
Primary antibody labeling simplifies assays, enables multiplexing and eliminates the cross-reactivity seen with secondary antibodies – helping you to streamline your workflow, increase your flexibility and improve reproducibility.
Improving Efficiency in Drug Discovery and Preclinical Development
Creating and bringing new drugs to the market can bring huge productivity challenges as the already complex drug development process becomes lengthier and more expensive.
Antibody Candidates Against GPCR Therapeutic Targets
Immunotherapy has the potential to treat a wide variety of conditions, from autoimmune disease to cancer. However, the discovery of potential antibody therapeutics against key receptor proteins remains a major challenge for the traditional immunisation approaches currently available on the market.
Research Tools for Anti-Cancer Drug Targets
Currently, various treatments are available to cancer patients, such as chemotherapy, targeted therapy and immunotherapy. Targeted therapy is a type of precision medicine that targets the proteins that control the growth, division and spread of cancer cells.